Beta BionicsvsMerck & Company

BBNX and MRK stock compared: price, dividend, valuation and results, from SEC filings.

BBNX

Beta Bionics, Inc.

$14.33

Value $779M

-2.65%
BBNX's page

MRK

Merck & Company, Inc.

$137.78

Value $341B

-3.90%
MRK's page

Beta Bionics (BBNX) has a market value of $779M and Merck & Company (MRK) $341B. Over the last year, with dividends, BBNX moved -47.2% and MRK +52.7%. Dividend yield: BBNX none, MRK 2.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BBNX$779M

    MRK$341B

    MRK is 437 times BBNX

  • Revenue, 12 months

    BBNX$127M

    MRK$67.4B

    MRK is 529 times BBNX

  • Net income, 12 months

    BBNX-$83M

    MRK$2.5B

  • Operating margin

    BBNX-72.8%

    MRK–

  • ROIC

    BBNX-24.2%

    MRK3.9%

    28.1 points apart

  • P/E

    BBNX–

    MRK138.9

  • Dividend yield

    BBNX0.0%

    MRK2.5%

    2.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BBNX-47.2%

MRK+52.7%

50100150DecFebAprJunAugOct
Returns by period
PeriodBBNXWith dividendsMRKWith dividends
1 year since November 17, 2025-47.2%Price -47.2%+52.7%Price +48.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BBNXBeta BionicsMRKMerck & Company

Valuation

BBNXMRK
Valuation
Price$14.33$137.78
Market value$779M$341B
Enterprise value (EV)$539M$385B
P/E–138.9
P/E, 5-year median–14.8
P/B1.97.6
EV/EBIT–80.8
Free cash flow yield–4.3%

Results and growth

BBNXMRK
Results and growth
Revenue, 12 months$127M$67.4B
Net income, 12 months-$83M$2.5B
Free cash flow, 12 months-$66M$14.7B
Earnings per share, 12 months-$1.83$0.98
Revenue growth, year on year53.9%1.3%
Revenue growth a year, past+189.1%over 2 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

BBNXMRK
Margins and returns on capital
Gross margin58.6%71.8%
Operating margin-72.8%–
Net margin-65.3%3.6%
ROIC-24.2%3.9%
ROE-27.5%5.2%

Balance sheet

BBNXMRK
Balance sheet
Cash$240M$9.7B
Total debt$6.2M$53.8B
Net debt / EBITDA–5.7
Interest cover–2.4×

Dividends and buybacks

BBNXMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BBNX or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Beta Bionics or Merck & Company?

By market value, Merck & Company ($341B) is about 437.2 times Beta Bionics ($779M), at today's prices.

How did BBNX and MRK stock do over the last 1 years?

Since November 17, 2025, BBNX's price moved -47.2% and MRK's +48.4%. With dividends: BBNX -47.2% (-47.2% a year), MRK +52.7% (+52.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, BBNX or MRK?

The dividend yield at today's price is none for Beta Bionics and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Beta Bionics or Merck & Company?

Over the last twelve months, the net margin was -65.3% for Beta Bionics and 3.6% for Merck & Company, and the operating margin -72.8% and –. Revenue was $127M and $67.4B.

Which is the better investment, Beta Bionics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.